CHARLES SWEET: Open Payments
NPI 1164568283 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,432 in 81 payments from 21 companies in 2025. Trend: 2023 $2,303 · 2024 $1,627 · 2025 $2,432
Food & beverage: $2,432
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 10 | $353 |
| Alkermes, Inc. | 7 | $292 |
| Vanda Pharmaceuticals Inc. | 6 | $282 |
| Teva Pharmaceuticals USA, Inc. | 5 | $185 |
| Axsome Therapeutics, Inc. | 7 | $183 |
| Janssen Scientific Affairs, LLC | 2 | $174 |
| Otsuka America Pharmaceutical, Inc. | 7 | $169 |
| Supernus Pharmaceuticals, Inc. | 6 | $166 |
| Corium, LLC | 6 | $113 |
| Lundbeck LLC | 4 | $106 |
Products named: FANAPT, REXULTI, COBENFY, SPRAVATO, ARISTADA, AUSTEDO XR, Auvelity, Qelbree.
Industry payments across TX — which companies pay providers there.
